Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
51
KRYS Quote, Financials, Valuation and Earnings
Last price:
$275.75
Seasonality move
:
5.2%
Day range:
$266.96 - $277.03
52-week range:
$122.80 - $298.30
Dividend yield:
0%
P/E ratio:
40.38x
P/S ratio:
21.25x
P/B ratio:
6.62x
Volume:
215.4K
Avg. volume:
304.7K
1-year change:
56.68%
Market cap:
$8.1B
Revenue:
$389.1M
EPS (TTM):
$6.84
Analysts' Opinion
-
Consensus RatingKrystal Biotech, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $313.22, Krystal Biotech, Inc. has an estimated upside of 13.34% from its current price of $276.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $241.00 representing 12.8% downside risk from its current price of $276.36.
Fair Value
-
According to the consensus of 10 analysts, Krystal Biotech, Inc. has 13.34% upside to fair value with a price target of $313.22 per share.
KRYS vs. S&P 500
-
Over the past 5 trading days, Krystal Biotech, Inc. has overperformed the S&P 500 by 5.22% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Krystal Biotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Krystal Biotech, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Krystal Biotech, Inc. reported revenues of $107.1M.
Earnings Growth
-
Krystal Biotech, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Krystal Biotech, Inc. reported earnings per share of $1.70.
Enterprise value:
7.3B
EV / Invested capital:
5.91x
Price / LTM sales:
21.25x
EV / EBIT:
45.06x
EV / Revenue:
18.66x
PEG ratio (5yr expected):
0.31x
EV / Free cash flow:
38.43x
Price / Operating cash flow:
43.78x
Enterprise value / EBITDA:
43.30x
Gross Profit (TTM):
$359.9M
Return On Assets:
17.53%
Net Income Margin (TTM):
52.64%
Return On Equity:
19.22%
Return On Invested Capital:
19.06%
Operating Margin:
41.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $50.7M | $290.5M | $389.1M | $91.1M | $107.1M | |
| Gross Profit | $42.6M | $263.8M | $359.9M | $84.6M | $99M | |
| Operating Income | -$97.2M | $103.2M | $161.1M | $41.4M | $44.3M | |
| EBITDA | -$92.2M | $109.9M | $167.7M | $43M | $46M | |
| Diluted EPS | $0.09 | $2.99 | $6.84 | $1.52 | $1.70 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $442.3M | $383.8M | $587.9M | $742M | $1B | |
| Total Assets | $626.3M | $558.5M | $818.4M | $1.1B | $1.3B | |
| Current Liabilities | $25.7M | $28.8M | $33.1M | $102M | $102.9M | |
| Total Liabilities | $32.7M | $36.2M | $39.7M | $109.5M | $114.2M | |
| Total Equity | $593.6M | $522.2M | $778.6M | $946.4M | $1.2B | |
| Total Debt | $7M | $7.4M | $6.6M | $6M | $7.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$88.8M | $123.4M | $200.9M | $52.8M | $77.5M | |
| Cash From Investing | $82.6M | -$163.4M | -$58.4M | -$83.8M | $11.2M | |
| Cash From Financing | $202.8M | $27M | $8.7M | $2.4M | $15.7M | |
| Free Cash Flow | -$100.6M | $119.2M | $188.9M | $52M | $75.4M | |
KRYS
Sector
Market Cap
$8.1B
$25.8M
Price % of 52-Week High
92.64%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
-0.32%
-1.64%
1-Year Price Total Return
56.68%
-18.88%
Beta (5-Year)
0.493
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$273.24
200-day SMA
Buy
Level
$189.69
Bollinger Bands (100)
Buy
Level
199.08 - 270.3
Chaikin Money Flow
Buy
Level
6.2M
20-day SMA
Buy
Level
$273.93
Relative Strength Index (RSI14)
Buy
Level
53.31
ADX Line
Buy
Level
15.98
Williams %R
Neutral
Level
-48.0222
50-day SMA
Buy
Level
$266.11
MACD (12, 26)
Buy
Level
1.32
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
39M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (39.3467)
Buy
CA Score
(Annual)
Level (2.1367)
Sell
Beneish M-Score
(Annual)
Level (29.4027)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-6.7839)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Stock Forecast FAQ
In the current month, KRYS has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KRYS average analyst price target in the past 3 months is $313.22.
-
Where Will Krystal Biotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Krystal Biotech, Inc. share price will rise to $313.22 per share over the next 12 months.
-
What Do Analysts Say About Krystal Biotech, Inc.?
Analysts are divided on their view about Krystal Biotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Krystal Biotech, Inc. is a Sell and believe this share price will drop from its current level to $241.00.
-
What Is Krystal Biotech, Inc.'s Price Target?
The price target for Krystal Biotech, Inc. over the next 1-year time period is forecast to be $313.22 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KRYS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Krystal Biotech, Inc. is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KRYS?
You can purchase shares of Krystal Biotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Krystal Biotech, Inc. shares.
-
What Is The Krystal Biotech, Inc. Share Price Today?
Krystal Biotech, Inc. was last trading at $275.75 per share. This represents the most recent stock quote for Krystal Biotech, Inc.. Yesterday, Krystal Biotech, Inc. closed at $276.36 per share.
-
How To Buy Krystal Biotech, Inc. Stock Online?
In order to purchase Krystal Biotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KRYS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KRYS
Sector
P/E ratio
40.38x
23.44x
PEG ratio
0.31x
-0.01x
P/B ratio
6.62x
1.81x
Price / LTM sales
21.25x
1.56x
Growth Metrics
KRYS
Sector
Revenue growth
17.52%
3.27%
Earnings growth
11.65%
9.66%
Revenue (5-year growth)
--
6.43%
Earnings forecast
$1.61
-$0.20
Profitability
KRYS
Sector
Profitability FY 2025
$360.4M
$2.3M
Return on invested capital
19.06%
-33.49%
Return on assets
17.53%
-29.74%
Return on equity
19.22%
-39.33%
Earnings Date
Last Earnings Date
Feb
17
Next Earnings Date
May
4
Estimated Next Earnings Date
May
19
Balance Sheet
KRYS
Sector
Total cash
$827.8M
$24.2M
Short term investments
$252.7M
$23.8M
Total assets
$1.3B
$71.1M
Long term debt
$7.6M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
